Summary
The pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) was studied in six patients with various advanced neoplastic diseases who received 28–72 mg/m2 DOX (nine courses). Plasma and parotid saliva were collected over a 48-h period, and DOX and DOXol were quantified by high-performance liquid chromatography with fluorescence detection. As reported previously, a wide range of plasma levels were found among our patients. It appears that in addition to being quickly cleared from the plasma, both DOX and DOXol are excreted in detectable amounts in parotid saliva, a route of elimination that has been given little attention, if any. Excretion in the saliva exposes the mucosa of the upper gastroinfestinal tract to drug and may play a role in causing stomatitis in patients receiving DOX by the i.v. route. Since huge interindividual and pronounced intraindividual differences were found in S/P ratios that mostly were not systematically related to the plasma drug concentration, the concentration in parotid saliva was not useful in predicting the level of free DOX and DOXol in plasma. For the parent drug and its metabolite, the S/P ratios increased significantly with time during the 48-h period after dosing.
This is a preview of subscription content, log in via an institution to check access.
References
Carter SK (1975) Adriamycin—a review. J Natl Cancer Inst 55: 1265
Celio LA, DiGregorio GJ, Ruch E, Pace JN, Piraino AJ (1982) Doxorubicin concentrations in rat plasma, parotid saliva, and bile and protein binding in rat plasma. Arch Int Pharmacodyn Ther 260: 180
Celio LA, DiGregorio GJ, Ruch E, Pace JN, Piraino AJ (1983) Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol 24: 261
Gomeni R (1984) PHARM: an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 14: 2534
Gomeni C, Gomeni R (1987) SIPHAR: an integrated computer system for statistical and pharmacokinetic data analysis. Proceedings, 7th International Congress of Medical Informatics, Europe 87, Rome, September 1987, pp 507–516
Jacquet J, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, Rossi JF (1990) Doxorubicin and doxorubicinol: intra-and inter-individual variations in pharmacokinetic parameters. Cancer Chemother Pharmacol 27: 219
Jacquet J, Galtier M, Bressolle F, Jourdan J (1992) A sensitive and reproducible HPLC assay for doxorubicin and pirarubicin. J Pharm Biomed Anal (in press)
Robert J (1980) Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liquid Chromatogr 3: 1561
Robert J, Shiadis A, Moerni B, Cano JP, Durand M, Lagarde C (1982) Pharmacokinetics of Adriamycin in patients with breast cancer: correlation between pharmacokinetic parameter and clinical short-term response. Eur J Cancer Clin Oncol 18: 739
Robert J, Vrignaud P, Sliadis A, Eghbali H, Hoerni B (1983) Etude pharmacocinétique de la doxorubicine dans le traitement des lymphomes malins non hodgkiniens. Nouv Rev Fr Hematol 25: 91
Robert J, Bui NB, Vrignaud P (1987) Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 31: 695
Wilkinson PM, Israel M, Pegg WJ, Frei E (1979) Comparative metabolism and excretion of Adriamycin in man, monkey and rat (III). Cancer Chemother Pharmacol 2: 121
Young RC, Ozoh RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305: 139
Author information
Authors and Affiliations
Additional information
This work was supported by a grant from the Association pour la Recherche sur le Cancer (Villejuif, France)
Rights and permissions
About this article
Cite this article
Bressolle, F., Jacquet, JM., Galtier, M. et al. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother. Pharmacol. 30, 215–218 (1992). https://doi.org/10.1007/BF00686315
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686315